Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5967099 | 0.99 | MMP8 (0.42) | MMP8ALDH1A1RECQLTAAR1PIN1 | |
| SCHEMBL27532935 | 0.85 | LTA4H (0.40) | MMP8ALDH1A1RECQLTAAR1LTA4H | |
| SCHEMBL8115153 | 0.81 | ALDH1A1 (0.58) | MMP8ALDH1A1RECQLTAAR1PIN1 | |
| SCHEMBL8105819 | 0.78 | ALDH1A1 (0.45) | MMP8ALDH1A1RECQLTAAR1PIN1 | |
| SCHEMBL19663910 | 0.73 | MMP8 (0.46) | MMP8ALDH1A1RECQLPIN1MAPT | |
| SCHEMBL25567671 | 0.73 | RORC (0.53) | TAAR1MAPTLTA4H | |
| SCHEMBL28008253 | 0.72 | PIN1 (0.49) | MMP8ALDH1A1RECQLPIN1MAPT | |
| SCHEMBL28308257 | 0.71 | PIN1 (0.45) | MMP8ALDH1A1RECQLPIN1MAPT | |
| SCHEMBL1455978 | 0.71 | PIN1 (0.51) | MMP8ALDH1A1RECQLPIN1MAPT | |
| SCHEMBL27752471 | 0.71 | PIN1 (0.51) | MMP8ALDH1A1RECQLPIN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | MMP8 817/4885ALDH1A1 3699/4885RECQL 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.